Search research articles
Contact Us
Filters
Showing results (1-10 of 12) with videos related to
Page
of 2
Sort By:
Current Neuropharmacology
|
March 25, 2026
Ocrelizumab Discontinuation vs. Continuation After Safety Events: Comparative Insights from MSBase
Aurora Zanghì, Tim Spelman, Marzena Fabis-Pedrini, et al.
Multiple Sclerosis and Related Disorders
|
January 30, 2026
Elevated serum complement shows promise as a potential clinically practical biomarker for disease activity in myelin oligodendrocyte glycoprotein antibody-associated disorders
Yiying Huang, Linling Wang, Marzena Fabis-Pedrini, et al.
Journal of Neurology
|
July 2, 2021
NMOSD and MS prevalence in the Indigenous populations of Australia and New Zealand
Wajih Bukhari, Elham Khalilidehkordi, Deborah F Mason, et al.
Annals of Clinical and Translational Neurology
|
July 29, 2024
The clinical relevance of MOG antibody testing in cerebrospinal fluid
Molly Reynolds, Irene Tan, Kristy Nguyen, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
September 1, 2017
Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis
Tomas Kalincik, Vilija Jokubaitis, Tim Spelman, et al.
Journal of Neurology
|
June 27, 2024
A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemic
Anoushka P Lal, Yi Chao Foong, Paul G Sanfilippo, et al.
Journal of Neurology
|
April 19, 2026
Predicting disease progression in multiple sclerosis with clinically accessible information and technology
Tom A N Fuchs, Menno M Schoonheim, Eva M M Strijbis, et al.
NPJ Digital Medicine
|
July 24, 2025
Personalized federated learning for predicting disability progression in multiple sclerosis using real-world routine clinical data
Ashkan Pirmani, Edward De Brouwer, Ádám Arany, et al.
Journal of Neurology
|
February 3, 2026
Effect of late-onset on multiple sclerosis phenotype and outcome: evidence from a multi-national registry
Amira Souissi, Francesco Patti, Tim Spelman, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
May 20, 2026
Comparative effectiveness of ocrelizumab in subgroups of patients with multiple sclerosis: a multi-registry observational cohort study
Izanne Roos, Sifat Sharmin, Dana Horakova, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 12) with videos related to
Sort By:
Page
of 2
Current Neuropharmacology
|
March 25, 2026
Ocrelizumab Discontinuation vs. Continuation After Safety Events: Comparative Insights from MSBase
Aurora Zanghì, Tim Spelman, Marzena Fabis-Pedrini, et al.
Multiple Sclerosis and Related Disorders
|
January 30, 2026
Elevated serum complement shows promise as a potential clinically practical biomarker for disease activity in myelin oligodendrocyte glycoprotein antibody-associated disorders
Yiying Huang, Linling Wang, Marzena Fabis-Pedrini, et al.
Journal of Neurology
|
July 2, 2021
NMOSD and MS prevalence in the Indigenous populations of Australia and New Zealand
Wajih Bukhari, Elham Khalilidehkordi, Deborah F Mason, et al.
Annals of Clinical and Translational Neurology
|
July 29, 2024
The clinical relevance of MOG antibody testing in cerebrospinal fluid
Molly Reynolds, Irene Tan, Kristy Nguyen, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
September 1, 2017
Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis
Tomas Kalincik, Vilija Jokubaitis, Tim Spelman, et al.
Journal of Neurology
|
June 27, 2024
A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemic
Anoushka P Lal, Yi Chao Foong, Paul G Sanfilippo, et al.
Journal of Neurology
|
April 19, 2026
Predicting disease progression in multiple sclerosis with clinically accessible information and technology
Tom A N Fuchs, Menno M Schoonheim, Eva M M Strijbis, et al.
NPJ Digital Medicine
|
July 24, 2025
Personalized federated learning for predicting disability progression in multiple sclerosis using real-world routine clinical data
Ashkan Pirmani, Edward De Brouwer, Ádám Arany, et al.
Journal of Neurology
|
February 3, 2026
Effect of late-onset on multiple sclerosis phenotype and outcome: evidence from a multi-national registry
Amira Souissi, Francesco Patti, Tim Spelman, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
May 20, 2026
Comparative effectiveness of ocrelizumab in subgroups of patients with multiple sclerosis: a multi-registry observational cohort study
Izanne Roos, Sifat Sharmin, Dana Horakova, et al.
Page
of 2